<?xml version='1.0' encoding='utf-8'?>
<document id="30588869"><sentence text="Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes."><entity charOffset="64-74" id="DDI-PubMed.30588869.s1.e0" text="eletriptan" /></sentence><sentence text="1" /><sentence text=" Pharmacokinetic drug-drug interaction (DDI) data is important from a label claim either in combination drug usage or in polypharmacy situation" /><sentence text=" 2" /><sentence text=" Eletriptan undergoes first pass related metabolism through CYP3A4 enzyme to form pharmacologically active N-desmethyl metabolite"><entity charOffset="1-11" id="DDI-PubMed.30588869.s5.e0" text="Eletriptan" /><entity charOffset="107-118" id="DDI-PubMed.30588869.s5.e1" text="N-desmethyl" /><pair ddi="false" e1="DDI-PubMed.30588869.s5.e0" e2="DDI-PubMed.30588869.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30588869.s5.e0" e2="DDI-PubMed.30588869.s5.e1" /></sentence><sentence text=" 3" /><sentence text=" Differential DDI interaction of the concomitant oral dosing of ketoconazole (20"><entity charOffset="64-76" id="DDI-PubMed.30588869.s7.e0" text="ketoconazole" /></sentence><sentence text="1 mg/kg), a CYP3A4 inhibitor, with oral (4" /><sentence text="2 mg/kg) or subcutaneous dose (2" /><sentence text="1 mg/kg) of eletriptan was evaluated in male Sprague Dawley rats"><entity charOffset="12-22" id="DDI-PubMed.30588869.s10.e0" text="eletriptan" /></sentence><sentence text=" Serial pharmacokinetic samples were collected and simultaneously analysed for eletriptan/N-desmethyl eletriptan using validated assay"><entity charOffset="79-89" id="DDI-PubMed.30588869.s11.e0" text="eletriptan" /><entity charOffset="90-112" id="DDI-PubMed.30588869.s11.e1" text="N-desmethyl eletriptan" /><pair ddi="false" e1="DDI-PubMed.30588869.s11.e0" e2="DDI-PubMed.30588869.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30588869.s11.e0" e2="DDI-PubMed.30588869.s11.e1" /></sentence><sentence text=" Non-compartmentally derived pharmacokinetic parameters for various treatments were analysed statistically" /><sentence text=" 4" /><sentence text=" After oral eletriptan in presence of ketoconazole, Cmax (40 vs"><entity charOffset="12-22" id="DDI-PubMed.30588869.s14.e0" text="eletriptan" /><entity charOffset="38-50" id="DDI-PubMed.30588869.s14.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.30588869.s14.e0" e2="DDI-PubMed.30588869.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30588869.s14.e0" e2="DDI-PubMed.30588869.s14.e1" /></sentence><sentence text=" 32 ng/mL alone) and AUCinf (81 vs" /><sentence text=" 24 ng" /><sentence text="h/mL alone) of eletriptan increased; the formation of N-desmethyl eletriptan decreased (Cmax=1"><entity charOffset="15-25" id="DDI-PubMed.30588869.s17.e0" text="eletriptan" /><entity charOffset="54-76" id="DDI-PubMed.30588869.s17.e1" text="N-desmethyl eletriptan" /><pair ddi="false" e1="DDI-PubMed.30588869.s17.e0" e2="DDI-PubMed.30588869.s17.e0" /><pair ddi="false" e1="DDI-PubMed.30588869.s17.e0" e2="DDI-PubMed.30588869.s17.e1" /></sentence><sentence text="1 ng/mL, 3" /><sentence text="9%) with ketoconazole as compared to without treatment (Cmax=3"><entity charOffset="9-21" id="DDI-PubMed.30588869.s19.e0" text="ketoconazole" /></sentence><sentence text="7 ng/mL, 11" /><sentence text="2%)" /><sentence text=" After subcutaneous eletriptan in presence of ketoconazole, there was no change in Cmax (153 vs"><entity charOffset="20-30" id="DDI-PubMed.30588869.s22.e0" text="eletriptan" /><entity charOffset="46-58" id="DDI-PubMed.30588869.s22.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.30588869.s22.e0" e2="DDI-PubMed.30588869.s22.e0" /><pair ddi="false" e1="DDI-PubMed.30588869.s22.e0" e2="DDI-PubMed.30588869.s22.e1" /></sentence><sentence text="152 ng/mL) or AUCinf (267 vs" /><sentence text=" 266 ng" /><sentence text="h/mL) of eletriptan"><entity charOffset="9-19" id="DDI-PubMed.30588869.s25.e0" text="eletriptan" /></sentence><sentence text=" Formation of N-desmethyl eletriptan after the subcutaneous dose was determined at few intermittent time points with/without ketoconazole"><entity charOffset="14-36" id="DDI-PubMed.30588869.s26.e0" text="N-desmethyl eletriptan" /><entity charOffset="125-137" id="DDI-PubMed.30588869.s26.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.30588869.s26.e0" e2="DDI-PubMed.30588869.s26.e0" /><pair ddi="false" e1="DDI-PubMed.30588869.s26.e0" e2="DDI-PubMed.30588869.s26.e1" /></sentence><sentence text=" 5" /><sentence text=" Preclinical data support differential DDI of eletriptan when dosed oral vs"><entity charOffset="46-56" id="DDI-PubMed.30588869.s28.e0" text="eletriptan" /></sentence><sentence text=" subcutaneous, which need to be evaluated in a clinical setting" /><sentence text="" /></document>